A multicenter, site-independent, blinded study to compare the diagnostic accuracy of contrast-enhanced magnetic resonance angiography using 1.0M gadobutrol (Gadovist™) to intraarterial digital subtraction angiography in body arteries

High-resolution 3D non-contrast-enhanced, ECG-gated, multi-step MR angiography of the lower extremities: Comparison with contrast-enhanced MR angiography

“…Nevertheless, the excellent diagnostic accuracy of multistep contrast-enhanced MRA in comparison to invasive digital subtraction angiography is already documented in patients with suspected PVD [4,8,9]. The use of a 1-molar gadolinium chelate is advantageous with regard to image quality in comparison to 0.5-molar gadolinium chelate [5] and should be recommended if parallel imaging is used [8].…”

“…The use of 1.0-molar gadobutrol for ceMRA has been validated against invasive catheterisation and could be considered a non-invasive clinical reference method [3][4][5].…”

Prognosis of intracranial dissection relates to site and presenting features

“…12,13 Due to the rarity of intracranial dissection, there have been no randomized, controlled studies to guide treatment. This has led to two major issues in its acute management:…”

Intra-individual, randomised comparison of the MRI contrast agents gadobutrol and gadoterate in imaging the distal lower limb of patients with known or suspected osteomyelitis, evaluated in an off-site blinded read

“…Gadobutrol and gadoterate have been successfully tested in both animal and human studies for safety and diagnostic reliability [8][9][10][11][12][13][14][15]. In Europe, gadobutrol is currently approved for contrast enhancement in cranial and spinal MRI, MR Angiography and MRI of the liver and kidneys.…”